Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3858932 | 0.95 | F10 (0.48) | F10F2PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL3830439 | 0.85 | F10 (0.47) | F10F2IRAK4IRAK1SMN1; SMN2 | |
| SCHEMBL3831562 | 0.85 | F10 (0.46) | F10IRAK4IRAK1KLKB1SMN1; SMN2 | |
| SCHEMBL7409963 | 0.78 | F10 (0.49) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3830373 | 0.78 | F10 (0.54) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3833307 | 0.76 | F10 (0.56) | F10F2PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL3830432 | 0.74 | KLKB1 (0.51) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL22897205 | 0.73 | F10 (0.54) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL18623062 | 0.72 | KLKB1 (0.70) | KLKB1 | |
| SCHEMBL3830187 | 0.71 | F10 (0.72) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | claimed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |